{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:32Z","timestamp":1786987052640,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:08:03Z","timestamp":1773763683000},"page":"399-407.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial"],"prefix":"10.1016","volume":"26","author":[{"given":"Fjoralba","family":"Kristo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-632X","authenticated-orcid":false,"given":"Flora","family":"Mazerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Alin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8234-2896","authenticated-orcid":false,"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Behringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2811-4762","authenticated-orcid":false,"given":"Janina","family":"Jablonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibade","family":"Ashaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2026.03.011_bib0001","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.clml.2026.03.011_bib0002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17474086.2020.1793666","article-title":"Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review","volume":"13","author":"Dalal","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.clml.2026.03.011_bib0003","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.1998.16.12.3810","article-title":"BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP\/ABVD in patients with advanced-stage Hodgkin\u2019s lymphoma: interim report from a trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"16","author":"Diehl","year":"1998","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.011_bib0004","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2026.03.011_bib0005","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.011_bib0006","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-021-01386-z","article-title":"Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group","volume":"36","author":"Damaschin","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.011_sbref0007","year":"2025"},{"issue":"18","key":"10.1016\/j.clml.2026.03.011_bib0008","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in Patients With Relapsed\/Refractory Hodgkin\u2019s Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study","volume":"30","author":"Younes","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.clml.2026.03.011_bib0009","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.03.011_bib0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0011","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: Current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clml.2026.03.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.clml.2026.03.011_bib0013","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.NNR.0000289503.22414.79","article-title":"Background noise: the experience of chemotherapy-induced peripheral neuropathy","volume":"56","author":"Bakitas","year":"2007","journal-title":"Nurs Res"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms","volume":"35","author":"Kautio","year":"2008","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11764-014-0379-x","article-title":"Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer","volume":"9","author":"Jones","year":"2015","journal-title":"J Cancer Surviv"},{"issue":"10450","key":"10.1016\/j.clml.2026.03.011_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.03.011_bib0017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clml.2026.03.011_bib0018","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0895-4356(98)00040-7","article-title":"Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients","volume":"51","author":"Sneeuw","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2026.03.011_bib0019","unstructured":"Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium. 2001. Accessed July 22, 2025, https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"issue":"10","key":"10.1016\/j.clml.2026.03.011_bib0020","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.clml.2026.03.011_bib0021","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s11136-017-1626-1","article-title":"Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)","volume":"26","author":"Kieffer","year":"2017","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.clml.2026.03.011_bib0022","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/NCC.0000000000000596","volume":"42","author":"Smith","year":"2019","journal-title":"Cancer Nurs"},{"issue":"12","key":"10.1016\/j.clml.2026.03.011_bib0023","first-page":"4753","article-title":"Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy","volume":"27","author":"Yeo","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.03.011_bib0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/0970-9185.194772","article-title":"The American Statistical Association statement on P-values explained","volume":"32","author":"Yaddanapudi","year":"2016","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.clml.2026.03.011_bib0025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","article-title":"Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma","volume":"7","author":"Abramson","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0026","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.03.011_bib0028","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/0284186X.2021.1917776","article-title":"Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin\u2019s lymphoma; symptom burden and quality of life","volume":"60","author":"Eikeland","year":"2021","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.03.011_bib0029","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.clml.2026.03.011_bib0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/djab017","article-title":"Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials","volume":"113","author":"Basch","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.clml.2026.03.011_bib0031","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2026.03.011_bib0032","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.clml.2026.03.011_bib0033","first-page":"3661","article-title":"Reconsidering tolerability of cancer treatments: opportunities to focus on the patient","volume":"30","author":"Peipert","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2026.03.011_bib0034","article-title":"Broadening the definition of tolerability in cancer clinical trials to capture the patient experience","author":"Basch","year":"2020","journal-title":"Friends of Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s13142-011-0025-3","article-title":"Stakeholder perspectives on implementing the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Bruner","year":"2011","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.clml.2026.03.011_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.clml.2026.03.011_bib0037","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11136-024-03740-x","article-title":"The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments","volume":"33","author":"Arizmendi","year":"2024","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0038","first-page":"37","article-title":"How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?","volume":"31","author":"Peipert","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.03.011_bib0039","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s41687-024-00823-8","article-title":"Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer","volume":"8","author":"Regnault","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.clml.2026.03.011_bib0040","first-page":"1","article-title":"[Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework","author":"Peipert","year":"2024","journal-title":"J Biopharm Stat"},{"issue":"2","key":"10.1016\/j.clml.2026.03.011_bib0041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jpainsymman.2021.07.031","article-title":"Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data","volume":"63","author":"Langlais","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1016\/j.clml.2026.03.011_bib0042","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djad018","article-title":"A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies","volume":"115","author":"Regnault","year":"2023","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:07:27Z","timestamp":1781251647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000741"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Development Center Americas, Inc., Cambridge, MA. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}